Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (131-140 of 191) with videos related to

Pageof 20
Sort By:
European Urology|May 23, 2024
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic ReviewAdam B Weiner, Preeti Kakani, Andrew J Armstrong, et al.
Urology|December 29, 2020
The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled TrialBilal Chughtai, Dean Elterman, Neal Shore, et al.
Urologic Oncology|March 26, 2017
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancerNicholas M Donin, Karim Chamie, Andrew T Lenis, et al.
Journal of Endourology|September 7, 2022
An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol DeviceDean Elterman, Mark N Alshak, Susana Martinez Diaz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
The Journal of Urology|August 9, 2023
Reply by AuthorsSteven A Kaplan, Jared Moss, Sheldon Freedman, et al.
European Urology Oncology|October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel TrialNoel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
Pageof 20

Showing results (131-140 of 191) with videos related to

Sort By:
Pageof 20
European Urology|May 23, 2024
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic ReviewAdam B Weiner, Preeti Kakani, Andrew J Armstrong, et al.
Urology|December 29, 2020
The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled TrialBilal Chughtai, Dean Elterman, Neal Shore, et al.
Urologic Oncology|March 26, 2017
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancerNicholas M Donin, Karim Chamie, Andrew T Lenis, et al.
Journal of Endourology|September 7, 2022
An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol DeviceDean Elterman, Mark N Alshak, Susana Martinez Diaz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
The Journal of Urology|August 9, 2023
Reply by AuthorsSteven A Kaplan, Jared Moss, Sheldon Freedman, et al.
European Urology Oncology|October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel TrialNoel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
Pageof 20